Mansi Saxena, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, comments on remaining unanswered questions regarding the development of cancer vaccines. Manufacturing costs remain high due to their personalized nature, and using shared neoantigens may led to off the shelf products, reducing cost. More advanced algorithms will additionally validate potential neoantigens, but achieving durable responses will be difficult using vaccines alone. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.